Latest Information Update: 23 Sep 2015
At a glance
- Originator Fortuderm
- Class Antipsoriatics
- Mechanism of Action Serotonin 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Plaque psoriasis
Most Recent Events
- 23 Sep 2015 No recent reports of development identified - Phase-I/II for Plaque psoriasis in Israel (Topical)
- 01 Oct 2012 Phase-I/II clinical trials in Plaque psoriasis in Israel (Topical)